(Q40127604)

English

Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma

scientific article published on 14 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

author name string

Robin Cornelissen

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Joost P J J Hegmans

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Alexander P W M Maat

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Margaretha E H Kaijen-Lambers

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Koen Bezemer

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Rudi W Hendriks

6

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Henk C Hoogsteden

7

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Joachim G J V Aerts

8

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

language of work or name

0 references

publication date

14 December 2015

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

American Journal of Respiratory and Critical Care Medicine

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

193

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1023-1031

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

New roads open up for implementing immunotherapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Immunomodulation in cancer

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

The Role of Regulatory T Cells in Mesothelioma.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4.

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Tumor-associated macrophages: from mechanisms to therapy

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

[F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Regulatory T cells in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201508-1573OC

21 January 2018

Identifiers

10.1164/RCCM.201508-1573OC

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40127604&oldid=1886251801"